Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limbs

X. Jia, Graham Mowatt, Jennifer Margaret Burr, Kevin Cassar, Jonathan Alistair Cook, Cynthia Mary Fraser

Research output: Contribution to journalArticle

226 Citations (Scopus)

Abstract

Background and method: Foam sclerotherapy is a potential treatment for varicose veins. A systematic review was undertaken to assess its safety and efficacy.

Results. Sixty-nine studies were included. The median rates of serious adverse events, including pulmonary embolism and deep vein thrombosis, were less than I per cent. The median rate of visual disturbance was 1.4 per cent, headache 4.2 per cent, thrombophlebitis 4.7 per cent, matting/skin staining/pigmentation 17.8 percent and pain at the site of injection 25.6 percent. The median rate of complete occlusion of treated veins was 87.0 per cent and for recurrence or development of new veins it was 8.1 per cent. Meta-analysis for complete occlusion suggests that foam sclerotherapy is less effective than surgery (relative risk (RR) 0.86 (95 per cent confidence interval (c.i.) 0-67 to 1.10)) but more effective than liquid sclerotherapy (RR 1.39 (95 percent c.i. 0.91 to 2.11)), although there was substantial heterogeneity between studies.

Conclusion: Serious adverse events associated with foam sclerotherapy are rare. There is insufficient evidence to allow a meaningfull comparison of the effectiveness of this treatment with that of other minimally invasive therapies or surgery.

Original languageEnglish
Pages (from-to)925-936
Number of pages11
JournalBritish Journal of Surgery
Volume94
Issue number8
Early online date16 Jul 2007
DOIs
Publication statusPublished - Aug 2007

Keywords

  • ultrasounded-guided injection
  • randomized controlled-trial
  • telangiectatic leg veins
  • polidocanol microfoam
  • sclerosing foam
  • management
  • efficacy
  • ulcers
  • safety
  • complications

Cite this

Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limbs. / Jia, X.; Mowatt, Graham; Burr, Jennifer Margaret; Cassar, Kevin; Cook, Jonathan Alistair; Fraser, Cynthia Mary.

In: British Journal of Surgery, Vol. 94, No. 8, 08.2007, p. 925-936.

Research output: Contribution to journalArticle

Jia, X. ; Mowatt, Graham ; Burr, Jennifer Margaret ; Cassar, Kevin ; Cook, Jonathan Alistair ; Fraser, Cynthia Mary. / Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limbs. In: British Journal of Surgery. 2007 ; Vol. 94, No. 8. pp. 925-936.
@article{2b26964895dd435da5e84d3f824bcf11,
title = "Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limbs",
abstract = "Background and method: Foam sclerotherapy is a potential treatment for varicose veins. A systematic review was undertaken to assess its safety and efficacy.Results. Sixty-nine studies were included. The median rates of serious adverse events, including pulmonary embolism and deep vein thrombosis, were less than I per cent. The median rate of visual disturbance was 1.4 per cent, headache 4.2 per cent, thrombophlebitis 4.7 per cent, matting/skin staining/pigmentation 17.8 percent and pain at the site of injection 25.6 percent. The median rate of complete occlusion of treated veins was 87.0 per cent and for recurrence or development of new veins it was 8.1 per cent. Meta-analysis for complete occlusion suggests that foam sclerotherapy is less effective than surgery (relative risk (RR) 0.86 (95 per cent confidence interval (c.i.) 0-67 to 1.10)) but more effective than liquid sclerotherapy (RR 1.39 (95 percent c.i. 0.91 to 2.11)), although there was substantial heterogeneity between studies.Conclusion: Serious adverse events associated with foam sclerotherapy are rare. There is insufficient evidence to allow a meaningfull comparison of the effectiveness of this treatment with that of other minimally invasive therapies or surgery.",
keywords = "ultrasounded-guided injection, randomized controlled-trial, telangiectatic leg veins, polidocanol microfoam, sclerosing foam, management, efficacy, ulcers, safety, complications",
author = "X. Jia and Graham Mowatt and Burr, {Jennifer Margaret} and Kevin Cassar and Cook, {Jonathan Alistair} and Fraser, {Cynthia Mary}",
year = "2007",
month = "8",
doi = "10.1002/bjs.5891",
language = "English",
volume = "94",
pages = "925--936",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "British Journal of Surgery",
number = "8",

}

TY - JOUR

T1 - Systematic review of the safety and efficacy of foam sclerotherapy for venous disease of the lower limbs

AU - Jia, X.

AU - Mowatt, Graham

AU - Burr, Jennifer Margaret

AU - Cassar, Kevin

AU - Cook, Jonathan Alistair

AU - Fraser, Cynthia Mary

PY - 2007/8

Y1 - 2007/8

N2 - Background and method: Foam sclerotherapy is a potential treatment for varicose veins. A systematic review was undertaken to assess its safety and efficacy.Results. Sixty-nine studies were included. The median rates of serious adverse events, including pulmonary embolism and deep vein thrombosis, were less than I per cent. The median rate of visual disturbance was 1.4 per cent, headache 4.2 per cent, thrombophlebitis 4.7 per cent, matting/skin staining/pigmentation 17.8 percent and pain at the site of injection 25.6 percent. The median rate of complete occlusion of treated veins was 87.0 per cent and for recurrence or development of new veins it was 8.1 per cent. Meta-analysis for complete occlusion suggests that foam sclerotherapy is less effective than surgery (relative risk (RR) 0.86 (95 per cent confidence interval (c.i.) 0-67 to 1.10)) but more effective than liquid sclerotherapy (RR 1.39 (95 percent c.i. 0.91 to 2.11)), although there was substantial heterogeneity between studies.Conclusion: Serious adverse events associated with foam sclerotherapy are rare. There is insufficient evidence to allow a meaningfull comparison of the effectiveness of this treatment with that of other minimally invasive therapies or surgery.

AB - Background and method: Foam sclerotherapy is a potential treatment for varicose veins. A systematic review was undertaken to assess its safety and efficacy.Results. Sixty-nine studies were included. The median rates of serious adverse events, including pulmonary embolism and deep vein thrombosis, were less than I per cent. The median rate of visual disturbance was 1.4 per cent, headache 4.2 per cent, thrombophlebitis 4.7 per cent, matting/skin staining/pigmentation 17.8 percent and pain at the site of injection 25.6 percent. The median rate of complete occlusion of treated veins was 87.0 per cent and for recurrence or development of new veins it was 8.1 per cent. Meta-analysis for complete occlusion suggests that foam sclerotherapy is less effective than surgery (relative risk (RR) 0.86 (95 per cent confidence interval (c.i.) 0-67 to 1.10)) but more effective than liquid sclerotherapy (RR 1.39 (95 percent c.i. 0.91 to 2.11)), although there was substantial heterogeneity between studies.Conclusion: Serious adverse events associated with foam sclerotherapy are rare. There is insufficient evidence to allow a meaningfull comparison of the effectiveness of this treatment with that of other minimally invasive therapies or surgery.

KW - ultrasounded-guided injection

KW - randomized controlled-trial

KW - telangiectatic leg veins

KW - polidocanol microfoam

KW - sclerosing foam

KW - management

KW - efficacy

KW - ulcers

KW - safety

KW - complications

U2 - 10.1002/bjs.5891

DO - 10.1002/bjs.5891

M3 - Article

VL - 94

SP - 925

EP - 936

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 8

ER -